239 results
6-K
EX-99
BLRX
Bioline Rx Ltd
6 May 24
Current report (foreign)
7:14am
evaluating the safety and efficacy of APHEXDA (motixafortide) plus filgrastim (G-CSF), compared to placebo plus filgrastim, for the mobilization … with multiple myeloma.5
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION
APHEXDA is indicated in combination with filgrastim (G-CSF
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
, multicenter study evaluating the safety and efficacy of APHEXDA (motixafortide) plus filgrastim (G-CSF), compared to placebo plus filgrastim … to the peripheral blood for collection and subsequent autologous stem cell transplantation in patients with multiple myeloma.6
INDICATION AND IMPORTANT SAFETY
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
business.
We deal with hazardous materials and must comply with environmental, health and safety laws and regulations, which can be expensive … ;
the efficacy and safety of the product;
our ability to offer the product for sale at competitive prices;
the product’s tolerability, convenience and ease
6-K
EX-99
hb98 ebyb4
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
hljeqk
16 Feb 24
Current report (foreign)
7:07am
6-K
EX-99
14tgbukdjea36yrfb
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
EX-99
r9p0qll
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
tlzk xylk
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
rs6lbaql
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
EX-99
z20uv xemhe1672s2
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
x61b8oi8gx6
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
z6fd nyywsrnox
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
cvi71i
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
2n2c9m7
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-1
8kmubd
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am
6-K
EX-99
cta353e
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
29ebgne nukvso5h8
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
yvpqbl67rqtmjg816
25 Apr 23
Current report (foreign)
7:07am